ClassID:

21055

A61K38/58 - CPC Classification

Classification description:

Medicinal preparations containing peptides; Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof; Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin

Recent Application in this class:
#1
20260124188
2026-05-07

mGluR receptor antagonists for use in prevention andor treatment of bone marrow lesions (BML) andor osteoporosis, cartilage loss, osteosclerosis and osteitis in a mammal

#2
20250367272
2025-12-04

HIRUDIN FORMULA COMPOSITION WITH ANTICOAGULANT AND HYPOLIPIDEMIC EFFECTS AND PREPARATION METHOD THEREOF

#3
20250228948
2025-07-17

METHODS OF TREATING OR PREVENTING STENT THROMBOSIS

#4
20250177502
2025-06-05

THROMBIN AND FIBRINOGEN AS TARGETS FOR ATOPIC DERMATITIS DIAGNOSIS AND TREATMENT

#5
20240350638
2024-10-24

METHODS OF TREATING OR PREVENTING STENT THROMBOSIS

#6
20240165194
2024-05-23

READY-TO-USE BIVALIRUDIN COMPOSITIONS

#7
20230293626
2023-09-21

Ready-to-use bivalirudin compositions

#8
20230263832
2023-08-24

TARGETED DRUG DELIVERY TO SITES OF INTRAVASCULAR OCCLUSION

#9
20230210938
2023-07-06

Ready-to-use bivalirudin compositions

#10
20230201298
2023-06-29

LIPOPROTEIN TARGETING PROTEASE INHIBITORS AND USES

#11
20230159629
2023-05-25

COMPOSITIONS AND METHOD OF MODULATING GROWTH FACTOR FUNCTION

#12
20230085357
2023-03-16

INJECTABLE HIGH CONCENTRATION PHARMACEUTICAL FORMULATIONS AND METHODS OF MANUFACTURING AND USE THEREOF

#13
20220249465
2022-08-11

UNIT DOSAGE FORM FOR TRANSMUCOSAL DRUG DELIVERY OF AN ACTIVE PHARMACEUTICAL INGREDIENT

#14
20220185872
2022-06-16

METHOD FOR INHIBITING PLATELET DERIVED GROWTH FACTOR SIGNALING WITH C3aR OR C5aR ANTIBODIES

#15
20220168379
2022-06-02

Lipoprotein targeting protease inhibitors and uses

#16
20220089777
2022-03-24

NOVEL HUMANIZED ANTIBODIES AGAINST FACTOR XI HAVING ANTI-THROMBOTIC AND ANTI-INFLAMMATORY EFFECT AND USES THEREOF

#17
20220056088
2022-02-24

PEPTIDE DIRECTED PROTEIN KNOCKDOWN

#18
20220008540
2022-01-13

METHODS OF TREATING OR PREVENTING STENT THROMBOSIS

#19
20200368311
2020-11-26

Ready-to-use bivalirudin compositions

#20
20200078434
2020-03-12

LIPOPROTEIN TARGETING PROTEASE INHIBITORS AND USES

#21
20190315819
2019-10-17

Peptide directed protein knockdown

#22
20190284258
2019-09-19

HAEMADIPSA SYLVESTRIS ANTITHROMBOTIC PEPTIDE SYLVESTIN AND USE THEREOF

#23
20190167796
2019-06-06

Methods of treating or preventing stent thrombosis

#24
20170360944
2017-12-21

Cardiovascular disease treatment and prevention

#25
20170354723
2017-12-14

Compositions and methods for cell transplantation

#26
20170319643
2017-11-09

LIPOPROTEIN TARGETING PROTEASE INHIBITORS AND USES

#27
20170224789
2017-08-10

STABLE INJECTABLE COMPOSITION OF BIVALIRUDIN AND PROCESS FOR ITS PREPARATION

#28
20170042940
2017-02-16

Compositions and methods for cell transplantation

#29
20160324943
2016-11-10

PROCESS FOR PRODUCTION OF BIVALIRUDIN

#30
20160324898
2016-11-10

COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE

#31
20160279195
2016-09-29

Factor XII inhibitors for the administration with medical procedures comprising contact with artificial surfaces

#32
20160158372
2016-06-09

Cardiovascular disease treatment and prevention

#33
20160106840
2016-04-21

AQUEOUS BUFFER-FREE BIVALIRUDIN COMPOSITIONS

#34
20150266935
2015-09-24

Peptide directed protein knockdown

#35
20150037291
2015-02-05

Factor Xa inhibitor used with liver-derived progenitor cells

#36
20140275226
2014-09-18

Method of controlling coagulation

#37
20140271801
2014-09-18

Cardiovascular disease treatment and prevention

#38
20130302291
2013-11-14

COMPOSITIONS AND METHODS FOR CELL TRANSPLANTATION

#39
20130224255
2013-08-29

Treatment of diabetic patients with a drug eluting stent and adjunctive therapy

#40
20130203674
2013-08-08

PROCESS FOR PRODUCTION OF BIVALIRUDIN

#41
20130196920
2013-08-01

PROCESS FOR PRODUCTION OF BIVALIRUDIN

#42
20130196919
2013-08-01

PROCESS FOR PRODUCTION OF BIVALIRUDIN

#43
20130196918
2013-08-01

PROCESS FOR PRODUCTION OF BIVALIRUDIN

#44
20130196917
2013-08-01

PROCESS FOR PRODUCTION OF BIVALIRUDIN

#45
20130196916
2013-08-01

PROCESS FOR PRODUCTION OF BIVALIRUDIN

#46
20130040898
2013-02-14

METHODS OF TREATMENT OF PATIENTS AT INCREASED RISK OF DEVELOPMENT OF ISCHEMIC EVENTS AND COMPOUNDS HEREOF

#47
20120315279
2012-12-13

Method for inhibiting platelet derived growth factor signaling with C3aR or C5aR antibodies

#48
20120201857
2012-08-09

Transdermal delivery system for therapeutics

#49
20120171259
2012-07-05

ORALLY ABSORBED PHARMACEUTICAL FORMULATION AND METHOD OF ADMINISTRATION

#50
20120052058
2012-03-01

METHODS OF MANAGING THE BLOOD COAGULATION AND PHARMACEUTICAL COMPOSITIONS RELATED THERETO

#51
20120052055
2012-03-01

Method of treating thrombocytopenia

#52
20110224150
2011-09-15

METHODS FOR EFFECTING REGRESSION OF TUMOR MASS AND SIZE IN A METASTASIZED TUMOR

#53
20110112030
2011-05-12

Methods of treating or preventing stent thrombosis

#54
20110046063
2011-02-24

READY-TO-USE BIVALIRUDIN COMPOSITIONS

#55
20110020272
2011-01-27

COMBINATION THERAPY FOR TREATING HEPATITIS VIRAL INFECTION

#56
20100273982
2010-10-28

PROCESS FOR PRODUCTION OF BIVALIRUDIN

#57
20100184729
2010-07-22

New Pharmaceutical Compositions for Treatment of Thrombosis

#58
20100178287
2010-07-15

USE OF COAGULATION PROTEINS TO LYSE CLOTS

#59
20100173947
2010-07-08

New Indications for Direct Thrombin Inhibitors

#60
20100029916
2010-02-04

PROCESS FOR PRODUCTION OF BIVALIRUDIN

#61
20090269422
2009-10-29

METHODS FOR CONTROLLING ANGIOGENESIS AND CELL PROLIFERATION

#62
20090247465
2009-10-01

Novel Use of Bivalirudin in the Treatment of Acute Coronary Syndrome

#63
20090214657
2009-08-27

Orally Absorbed Pharmaceutical Formulation and Method of Administration

#64
20090202621
2009-08-13

CELL-SURFACE DECORATION WITH ACTIVE AGENTS

#65
20080267969
2008-10-30

Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway

#66
20080220042
2008-09-11

Biomolecule-linked biomimetic scaffolds

#67
20080200514
2008-08-21

Indications for Direct Thrombin Inhibitors

#68
20080057096
2008-03-06

Biocompatible stent

#69
20080039391
2008-02-14

New Indications for Direct Thrombin Inhibitors in the Cardiovascular Field

#70
20080039362
2008-02-14

Combination drug therapy for reducing scar tissue formation

#71
20070275086
2007-11-29

Use of Increased Molecular-Weight Hirudin as an Anticoagulant in Extracorporeal Kidney Replace Therapy

#72
20070275055
2007-11-29

Compositions capable of facilitating penetration across a biological barrier

#73
20070259050
2007-11-08

Combined Cosmetic or Therapeutic Preparation

#74
20070248676
2007-10-25

Use of nitric oxide adducts

#75
20070110740
2007-05-17

Tissue preservation with a salt solution isotonic with interstitial fluids

#76
20070093423
2007-04-26

Process for production of Bivalirudin

#77
20070025979
2007-02-01

Coagulation proteins, coagulation-anticoagulation protein complexes, derivatives thereof and their uses

#78
20060275277
2006-12-07

Use of coagulation proteins to lyse clots

#79
20060222640
2006-10-05

NEW PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF THROMBOSIS

#80
20060210548
2006-09-21

Method for reducing obstructive hydrocephalus

#81
20060198836
2006-09-07

Method of treating hit patients with argatroban

#82
20060110425
2006-05-25

Leech extracts for stents

#83
20050233966
2005-10-20

Methods for effecting regression of tumor mass and size in a metastasized pancreatic tumor

#84
20050203007
2005-09-15

Eglin c based drugs for treatment of disease

#85
20050118274
2005-06-02

Method and device for feeding living cells into a biological body fluid

#86
20050084514
2005-04-21

Combination drug therapy for reducing scar tissue formation

#87
20050058702
2005-03-17

Compositions capable of facilitating penetration across a biological barrier